There is no doubt that SFPQ is a key regulator of the RUNX2 gene, and targeting the SFPQ site may be a potential strategy for the treatment of osteoarthritis, and even various human cancers that presence of high levels of RUNX2 [41]. The gene discussed is SFPQ; the disease is cancer.